[Federal Register Volume 61, Number 84 (Tuesday, April 30, 1996)]
[Notices]
[Page 19090]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-10616]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA # 144W]
Controlled Substances: 1996 Aggregate Production Quotas
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Withdrawal of an interim notice regarding levorphanol and
establishment of the revised 1996 aggregate production quota for
heroin.
-----------------------------------------------------------------------
SUMMARY: DEA is withdrawing the portion of the interim notice published
on March 18, 1996 (61 FR 11063) which established the revised 1996
aggregate production quota for levorphanol, and is adopting without
change the revised 1996 aggregate production quota for heroin.
FOR FURTHER INFORMATION CONTACT:
Howard McClain, Jr., Chief, Drug and Chemical Evaluation Section, Drug
Enforcement Administration, Washington DC, 20537, (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act
(21 U.S.C. 826), requires the Attorney General to establish aggregate
production quotas for controlled substances in Schedules I and II each
year. This responsibility has been delegated to the Administrator of
the DEA pursuant to Section 0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn, has redelegated this function
to the Deputy Administrator of the DEA pursuant to Section 0.104 of
Title 28 of the Code of Federal Regulations.
On March 18, 1996, an interim notice establishing revised 1996
aggregate production quotas for heroin and levorphanol was published in
the Federal Register (61 FR 11063). The basis for the proposed increase
in the levorphanol aggregate production quota was that there was only
one bulk manufacturer of levorphanol. A comment was filed that pointed
out that there is more than one manufacturer of levorphanol. Given that
this was the basis for the increase in the levorphanol aggregate
production quota, DEA is withdrawing the revised 1996 aggregate
production quota for levorphanol.
No comments were received regarding heroin, therefore, the revised
1996 aggregate production quota for heroin is adopted without change.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866. This action has been analyzed in accordance with
the principles and criteria contained in Executive Order 12612, and it
has been determined that this matter does not have sufficient
federalism implications to warrant the preparation of a Federalism
Assessment.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq.
The establishment of annual aggregate production quotas for Schedules I
and II controlled substances is mandated by law and by international
treaty obligations. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
Therefore, under the authority vested in the Attorney General by
Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826),
delegated to the Administrator of the DEA by Section 0.100 of Title 28
of the Code of Federal Regulations, and redelegated to the Deputy
Administrator, pursuant to Section 0.104 of Title 28 of the Code of
Federal Regulations, the Deputy Administrator hereby orders that the
revised 1996 aggregate production quota for heroin be established at 5
grams, expressed as anhydrous base.
Dated: April 24, 1996.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 96-10616 Filed 4-29-96; 8:45 am]
BILLING CODE 4410-09-M
